<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854759</url>
  </required_header>
  <id_info>
    <org_study_id>LUB-COV-2021-01</org_study_id>
    <nct_id>NCT04854759</nct_id>
  </id_info>
  <brief_title>The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms</brief_title>
  <acronym>COV-PREVENT</acronym>
  <official_title>The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Independent Public Clinical Hospital No. 4 in Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Independent Public Clinical Hospital No. 4 in Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in&#xD;
      patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind,&#xD;
      placebo-controlled, non-commercial clinical trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of clinical deterioration</measure>
    <time_frame>Up to day 15 from randomization</time_frame>
    <description>Defined as dyspnoea - physical examination - doctor's assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical deterioration occurs</measure>
    <time_frame>Up to day 15 from randomization</time_frame>
    <description>Defined as drop in O2 saturation (&lt;92% with patient exposure to room air) and / or additional oxygen demand to maintain O2 saturation ≥92%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical deterioration occurs</measure>
    <time_frame>Up to day 15 from randomization</time_frame>
    <description>Defined as achievement of ≥4 points on the WHO [OSCI-WHO] scale (7-point clinical status assessment scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General Health Scale (PROMIS® Global Health Scale)</measure>
    <time_frame>Day 15, 30 complementary visit-optional, 90, 150, 210</time_frame>
    <description>Mean Global Health scores for each arm at day 15, 30 complementary visit-optional, 90, 150, 210. PROMIS® instruments are scored using item-level calibrations. This method of scoring uses &quot;response pattern scoring,&quot; which uses responses to each item for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The neurological assessment</measure>
    <time_frame>Day 15, 30 complementary visit-optional, 90, 150, 210</time_frame>
    <description>will include the assessment of neurological functions based on:&#xD;
scales for fatigue,&#xD;
depression,&#xD;
disorders of smell and taste,&#xD;
sleep disorders,&#xD;
quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical deterioration</measure>
    <time_frame>Day 15, 30 complementary visit-optional, 90, 150, 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Day 15, 30 complementary visit-optional, 90, 150, 210</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine Hydrochloride</intervention_name>
    <description>100 mg, capsule</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mg, capsule</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 and over&#xD;
&#xD;
          -  Can give informed consent&#xD;
&#xD;
          -  Confirmed positive result for SARS-CoV-2 within 72 hours from the date the result was&#xD;
             issued (according to the laboratory report)&#xD;
&#xD;
          -  Patient presently symptomatic with one or more of the following symptoms: fever,&#xD;
             cough, myalgia, mild dyspnoea, chest pain, diarrhea, nausea, vomiting, anosmia, lack&#xD;
             of taste, sore throat, nasal congestion&#xD;
&#xD;
          -  At initial screening, the subject will report at least one and no more than 3 of the&#xD;
             following risk factors for clinical worsening: age ≥40, obesity, hypertension,&#xD;
             diabetes, pulmonary disease (e.g., asthma, COPD), and immune disorders (e.g.&#xD;
             rheumatoid arthritis, lupus), neurological diseases: e.g. after a distant stroke or&#xD;
             trauma to the brain, multiple sclerosis, dementia and other neurodegenerative&#xD;
             diseases)&#xD;
&#xD;
          -  Patients hospitalized due to meeting the above criteria and requiring observation in a&#xD;
             hospital or outpatient setting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease severe enough to meet the study's primary endpoint of clinical worsening (eg,&#xD;
             current O2 saturation &lt;92% with patient exposure to room air, current use of&#xD;
             supplemental oxygen to maintain O2 saturation ≥ 92%).&#xD;
&#xD;
          -  WHO score ≥4 (requires oxygen therapy during hospitalization)&#xD;
&#xD;
          -  Concomitant diseases which, in the opinion of the attending physician, prevent the&#xD;
             patient from participating in the study, such as: decompensated cirrhosis, active&#xD;
             ulcer disease, epilepsy and symptomatic convulsions, untreated angle-closure glaucoma&#xD;
             determined on the basis of the patient's interview and / or medical documentation . In&#xD;
             addition, immunocompromised patients (solid organ transplant, BMT, AIDS, renal failure&#xD;
             (patients with renal impairment may develop drug poisoning) or other diseases not&#xD;
             mentioned and other diseases treated with biological, immunological and / or steroids&#xD;
             in high doses will not be eligible for the study. doses (&gt; 20 mg prednisone daily).&#xD;
&#xD;
          -  Hypersensitivity to any component of the preparation, severe congestive heart failure,&#xD;
             cardiomyopathy, myocarditis, II-III degree AV block, bradycardia, clinically&#xD;
             significant prolongation of the QT interval, or a family history of congenital long QT&#xD;
             syndrome, severe ventricular arrhythmias (including torsade de pointes), concomitant&#xD;
             use of drugs that prolong the QT interval, hypokalaemia, hypomagnesaemia,&#xD;
&#xD;
          -  Pregnancy, the period of breastfeeding.&#xD;
&#xD;
          -  Parallel intake of memantine or other drugs acting on the CNS (neuroleptics,&#xD;
             anxiolytics, antiepileptic drugs, antidepressants).&#xD;
&#xD;
          -  Other neurological conditions with agitation or confusion, delirium syndromes or&#xD;
             psychoses.&#xD;
&#xD;
          -  Receipt of a partial or full vaccination schedule against SARS-CoV-2 is also an&#xD;
             exclusion criterion from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad Rejdak, Professor, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent Public Clinical Hospital No. 4 in Lublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad Rejdak, Professor, PhD, MD</last_name>
    <phone>81 72 44 720</phone>
    <phone_ext>0048</phone_ext>
    <email>konradrejdak@umlub.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paweł Pinkosz</last_name>
    <phone>81 72 44 484</phone>
    <phone_ext>0048</phone_ext>
    <email>pawel.pinkosz@spsk4.lublin.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny im. dr Władysława Biegańskiego Oddział Neurologii i Neuroimmunologii Klinicznej</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Bonek, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej w Kalwarii Zebrzydowskiej</name>
      <address>
        <city>Kalwaria Zebrzydowska</city>
        <zip>34-130</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mateusz Dec, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Obserwacyjno-Zakaźny SPSz Woj. Im. Jana Bożego Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-089</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slawomir Kiciak, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad Rejdak, Professor, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Chorób Wewnętrznych Nefrologii i Endokrynologii Klinicznego Szpitala Wojewódzkiego nr 2 im. Św. Jadwigi Królowej</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-301</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Gala- Błądzińska, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Szpital Kliniczny Dzieciątka Jezus</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Fiedor, Professor, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew J. Król, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Kardiologiczny Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Wyszkowie</name>
      <address>
        <city>Wyszków</city>
        <zip>07-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar Chełstowski, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 17, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

